NinePoint Medical Appoints Eman Namati, Ph.D., to Chief Executive Officer

Date Announced: 01 Jul 2018

Former CEO to remain on board of directors.

BEDFORD, Mass.--(BUSINESS WIRE)--NinePoint Medical, Inc, a transformative medical device company pioneering the use of Optical Coherence Tomography (OCT) for gastrointestinal applications, is pleased to announce the appointment of Eman Namati, Ph.D., to President and Chief Executive Officer. Dr. Namati succeeds Christopher von Jako, Ph.D., who will continue to serve on the Board of Directors as an independent member. Dr. Namati will assume day-to-day leadership at NinePoint Medical while working in collaboration with Merit Medical Systems Inc. (NASDAQ:MMSI), who now manages the sales distribution and customer service for the NvisionVLE^® Imaging System.

"With the recent strategic partnership NinePoint entered into with Merit Medical, along with Eman’s long history with the technology, business acumen, and strong leadership, this was a natural choice for the Board and a great next step for the company" said Tom Miller, Chairman of the Board of Directors. "In addition to Eman’s product vision, he has during his tenure at NinePoint established a track record of building and successfully leading diverse and highly technical teams through the development and commercialization of complex medical instruments. As we look towards future growth opportunities and expand into new indications, his experience and vision will be key to our success.”

“I am honored and incredibly excited to take on this leadership role during such a pivotal point in the company’s history and look forward to working with Merit Medical on our new strategic partnership. I would like to extend my sincere thanks to Chris for his service to NinePoint and mentorship to me over the past four-years. I am fortunate to be surrounded by a truly talented team with exciting and innovative products in the pipeline. Together, we look forward to continuing our important mission towards early detection of cancer,” said Dr. Namati.

Eman joined NinePoint Medical during its inception in 2010 as a technical co-founder and has served as the Vice President of Research and Development for the past four-years. He has overseen the development of highly complex imaging systems and single-use devices from concept through commercialization, including translation of the original academic prototype into the NvisionVLE® platform as well as the recently launched Real-time Targeting^TM laser marking system. Prior to his time at NinePoint, Dr. Namati was a researcher developing optical imaging systems at Massachusetts General Hospital. He worked with Professors Guillermo Tearney, M.D., Ph.D., and Brett Bouma, Ph.D. on the OCT technology that was licensed to NinePoint Medical. Dr. Namati holds a Ph.D. in Biomedical Engineering and a double undergraduate degree in Engineering (BE) and Science (BSc) from Flinders University Australia.

About the NvisionVLE^® Imaging System

The NvisionVLE Imaging System provides a unique and clinically valuable new perspective on esophageal disease - the ability to image within the wall of the esophagus. By providing a high-resolution, real-time scan of the esophagus using Optical Coherence Tomography (OCT) – a technology similar to ultrasound but using infrared light rather than sound waves - the system enables physicians to view structures not evident with conventional imaging, and potentially identify disease that would have otherwise been missed. With the recent addition of a Real-time Targeting^TM feature, physicians can not only locate, but now mark areas of interest. This marking feature, in combination with an improved workflow, enables more accurate targeting, potentially leading to improved diagnosis and more effective therapeutic decisions for patients.

The NvisionVLE Imaging System has been cleared by the FDA and is commercially available in the U.S. It is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and may be used to mark areas of tissue. The safety and efficacy of this device for diagnostic analysis (i.e. differentiating normal versus specific abnormalities) in any tissue microstructure or specific disease has not been evaluated.

Source: NinePoint Medical

Contact

E-mail: via web site

Web Site: www.ninepointmedical.com